Sidse Arnfred

Psychiatric Research Unit, Region Zealand Mental Health Service, Slagelse, Denmark.

2 papers in the library · 83 citations · publishing 2023

Papers

Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review

Journal of Psychopharmacology July 1, 2023 Oliver Rumle Hovmand, Emil Deleuran Poulsen, Sidse Arnfred et al. 52 citations

A systematic review of clinical trials on classical psychedelics (psilocybin, peyote, ayahuasca/DMT, and LSD) for psychiatric conditions found that all but one of the ten included trials were rated as high risk of bias. The trials predominantly enrolled white, highly educated participants, had small sample sizes, and experienced considerable dropout. Blinding was either unsuccessful or not reported regardless of the type of placebo used. Few trials published protocols, statistical analysis plans, or measures of psychotherapy fidelity. The authors suggest that future trials use parallel-group designs with active placebos in psychedelic-naïve populations, publish protocols and analysis plans, employ blinded clinician-rated outcomes, evaluate blinding, and measure expectancy and therapeutic fidelity.

DOI: 10.1177/02698811231180276 Randomized controlled trial Clinical trial Medline Medicine +2

Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics

Journal of Psychopharmacology November 16, 2023 Oliver Rumle Hovmand, Emil Deleuran Poulsen, Sidse Arnfred 31 citations

Classical psychedelics such as psilocybin, peyote, ayahuasca, and LSD can temporarily alter consciousness, affecting perception, mood, and sense of self. Reliable measurement tools are needed because the acute subjective experience may influence treatment outcomes. A review of 93 trials identified 17 different rating scales used to assess these altered states. The five most common instruments were the Five-Dimensional Altered States of Consciousness Questionnaire, visual analog or Likert scales developed for specific trials, the Hallucinogen Rating Scale, the States of Consciousness Questionnaire, and the Abnormer Psychischer Zustand. The authors recommend developing a core set of outcome measures to allow comparisons across different psychedelics, participants, and settings, and suggest designing instruments that assess the setting of the experience.

DOI: 10.1177/02698811231200019 Full text Ayahuasca Psilocybin Lysergic acid diethylamide Hallucinogen +7